BGNE - BeiGene, Ltd.
| Previous Close | 169.13 |
| Open | 168.28 |
| Bid | 165.33 x 100 |
| Ask | 180.00 x 100 |
| Day's Range | 168.28 - 173.35 |
| 52 Week Range | 34.36 - 182.79 |
| Volume | 394,713 |
| Avg. Volume | 408,095 |
| Market Cap | 9.136B |
| Beta | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool•7 days ago
These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years
Find out how these three put up huge gains while their peers struggled.
Market Realist•11 days agoWhat Drove BeiGene Stock in March 2018?
BeiGene (BGNE) stock has risen 16.9%, from $143.73 on March 1, 2018, to $168 on March 29, 2018. Originally founded as a research and development company, BeiGene has evolved into a biopharmaceutical company focused on developing oncology therapies such as BTK inhibitor zanubrutinib, PD-1 antibody tislelizumab, and PARP inhibitor pamiparib.
- Motley Fool•last month
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
These two highfliers have risen roughly fourfold over the past year. Here's how they could keep it going.
- Motley Fool•last month
The Revolutionary New HIV Drug You've Probably Never Heard Of
The FDA recently approved a groundbreaking new HIV treatment, and it isn't from Gilead or Glaxo.
- Motley Fool•2 months ago
These 2 Biotech Stocks Are Soaring. Can They Keep It Up?
Find out why these two stocks have surged this year to see if there might be more gains ahead.
- Motley Fool•2 months ago
Here's Why BeiGene, Ltd. Jumped 38.9% in January
Celgene Corporation's partner in China is getting busy with tislelizumab.
- Motley Fool•3 months ago
Celgene's Investments Are Soaring
The biotech Goliath's investment portfolio is paying off.
- Zacks•3 months ago
BeiGene (BGNE) Surges: Stock Moves 12.6% Higher
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
- Motley Fool•3 months ago
Why BeiGene Is Soaring 13.8% Today
The company's wallet is about to get a bit thicker.
Motley Fool•4 months agoThese Stocks Have Tripled Since Last Year
What's ahead for these red-hot companies in 2018?
Reuters•6 months agoChina biotech's 'coming out party' masks long road ahead
LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (LSE:HCM.L - News), Beigene (NasdaqGS:BGNE - News) and Zai Lab (NasdaqGM:ZLAB - News) have soared on international markets this year, fueled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (LSE:AZN.L - News).
